DHR

Danaaher Corporation 2007 10-K Summary

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2007. Danaher Corporation is a multinational manufacturer of professional, medical, industrial, and consumer products. The company operates through four segments: Professional Instrumentation, Medical Technologies, Industrial Technologies, and Tools & Components. Danaher utilizes the "Danaher Business System" (DBS) to drive operational improvements and pursues growth through organic expansion and strategic acquisitions.

Key Financial Metrics

Note: Net Earnings for 2007 includes a $150 million after-tax gain from the sale of the power quality business (discontinued operations).

Material Changes vs. Prior Period

• Acquisitions: Sales growth was driven significantly by acquisitions, which contributed 8.5% to total sales growth. Major 2007 acquisitions included Tektronix, Inc. (November 2007, ~$2.8 billion) and ChemTreat, Inc. (July 2007, $425 million). These deals expanded the Professional Instrumentation segment.
• Divestitures: The company sold its power quality business in July 2007 for $275 million, recording a $150 million after-tax gain. This business is now reported as discontinued operations.
• Segment Performance:
  • Professional Instrumentation: Sales increased 22.0% to $3,537.9 million, driven by Tektronix and ChemTreat.
  • Medical Technologies: Sales increased 35.0% to $2,998.0 million, driven by Sybron Dental and Vision Systems acquisitions.
  • Industrial Technologies: Sales increased 5.5% to $3,153.4 million.
  • Tools & Components: Sales decreased 1.0% to $1,336.6 million due to regulatory changes affecting engine retarder demand.
• Debt Levels: Total debt increased by approximately $1.3 billion to fund acquisitions, primarily through commercial paper and a new $500 million senior note issuance.

Guidance, Outlook, and Risks

• Outlook: Management expects the 2008 effective tax rate to be approximately 27%. Capital spending for 2008 is expected to exceed $200 million.
• Acquisition Strategy: The company continues to seek acquisition opportunities to drive growth, though integration risks and accounting changes (SFAS 141R) may impact future financial reporting.
• Risks:
  • Competition: Intense competition in diverse markets could lead to price reductions or decreased demand.
  • Acquisition Integration: Risks include under-performance of acquired businesses, integration difficulties, and assumption of unknown liabilities.
  • Regulatory & Environmental: Subject to FDA regulations for medical devices and environmental laws regarding hazardous waste. Non-compliance could result in penalties or operational disruptions.
  • Foreign Currency: Approximately 51% of sales are derived outside the U.S. A strengthening U.S. dollar could adversely impact reported sales and profits.
  • Commodity Prices: Increases in steel and petroleum-based product costs may impact margins if not passed on to customers.

Key Facts for Investor Verification

• Tektronix Integration: Verify the progress of integrating Tektronix, a late-year acquisition, and the realization of anticipated cost synergies.
• Discontinued Operations: Confirm that the $150 million gain from the power quality business sale is correctly classified as discontinued operations and does not inflate core operating metrics.
• Debt Servicing: Monitor the company's ability to service increased debt levels ($3.7 billion) and the impact of variable interest rates on commercial paper.
• Goodwill Impairment: With significant goodwill additions from 2007 acquisitions, verify the annual impairment testing results for the Professional Instrumentation and Medical Technologies segments.
• Regulatory Impact on Tools & Components: Assess the long-term impact of regulatory changes on the engine retarder business, which caused a sales decline in 2007.